MDGL 250516 270.00C(MDGL250516C270000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

MDGL250516C270000

Watchlist

75.00
0.000.00%

15min DelayClose May 6 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

New Analyst Forecast: $MDGL Given $420.0 Price Target
Quiver QuantitativeMay 6 10:24 ET
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Maintains Target Price $248
Moomoo NewsMay 6 07:32 ET · Ratings
Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities
Dow JonesMay 2 12:18 ET · Ratings
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Dow JonesMay 2 11:55 ET · Ratings
Madrigal Pharmaceuticals Analyst Ratings
BenzingaMay 2 11:44 ET · Ratings
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating
MT NewswiresMay 2 08:07 ET · Ratings

Comments

Teddy123

Feb 26 19:41

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH

$Madrigal Pharmaceuticals (MDGL.US)$
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?

Stock_Drift

Nov 1, 2024 23:33

Unusual Volume Ticks. 11:32am

$Madrigal Pharmaceuticals (MDGL.US)$ $Nuburu (BURU.US)$ $Pro-Dex (PDEX.US)$ $ASP Isotopes (ASPI.US)$ $GRI Bio (GRI.US)$ $Vast Renewables (VSTE.US)$ $MicroCloud Hologram (HOLO.US)$ $Theriva Biologics (TOVX.US)$ $Pluribus Technologies Corp (PLRB.CA)$ $Ensysce Biosciences (ENSC.US)$ $Athira (ATHA.US)$ $Globalstar (GSAT.US)$ $ChromaDex (CDXC.US)$
📊⚡️📊

Jerry Kronenberg

Jun 12, 2024 03:52

Columns Madrigal Pharmaceuticals Rallies 15% on Wolfe Research 'Outperform' Rating

$Madrigal Pharmaceuticals (MDGL.US)$ rose some 15% Tuesday after Wolfe Research reportedly initiated coverage of the pharma firm with a "Outperform" rating.
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...

Meltyy

May 16, 2024 14:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Meltyy

May 16, 2024 14:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...